Belatacept-based immunosuppression in de novo liver transplant recipients: 1-year experience from a phase II randomized study

Salvatore Agnes, G. B. Klintmalm, S. Feng, J. R. Lake, H. E. Vargas, T. Wekerle, K. A. Brown, B. Nashan, L. Rostaing, S. Meadows-Shropshire, M. Agarwal, M. B. Harler, J. C. García-Valdecasas

Risultato della ricerca: Contributo in rivistaArticolo in rivista

72 Citazioni (Scopus)

Abstract

This exploratory phase II study evaluated the safety and efficacy of belatacept in de novo adult liver transplant recipients. Patients were randomized (N = 260) to one of the following immunosuppressive regimens: (i) basiliximab + belatacept high dose [HD] + mycophenolate mofetil (MMF), (ii) belatacept HD + MMF, (iii) belatacept low dose [LD] + MMF, (iv) tacrolimus + MMF, or (v) tacrolimus alone. All received corticosteroids. Demographic characteristics were similar among groups. The proportion of patients who met the primary end point (composite of acute rejection, graft loss, death by month 6) was higher in the belatacept groups (42–48%) versus tacrolimus groups (15–38%), with the highest number of deaths and grafts losses in the belatacept LD group. By month 12, the proportion surviving with a functioning graft was higher with tacrolimus + MMF (93%) and lower with belatacept LD (67%) versus other groups (90%: basiliximab + belatacept HD; 83%: belatacept HD; 88%: tacrolimus). Mean calculated GFR was 15–34 mL/min higher in belatacept-treated patients at 1 year. Two cases of posttransplant lymphoproliferative disease and one case of progressive multifocal leukoencephalopathy occurred in belatacept-treated patients. Follow-up beyond month 12 revealed an increase in death and graft loss in another belatacept group (belatacept HD), after which the study was terminated.
Lingua originaleEnglish
pagine (da-a)1817-1827
Numero di pagine11
RivistaAmerican Journal of Transplantation
Volume14
DOI
Stato di pubblicazionePubblicato - 2014

Keywords

  • liver transplantation

Fingerprint

Entra nei temi di ricerca di 'Belatacept-based immunosuppression in de novo liver transplant recipients: 1-year experience from a phase II randomized study'. Insieme formano una fingerprint unica.

Cita questo